In our recent webinar, our team provided a detailed overview of Health Canada’s updated Good Manufacturing Practices (GMP) Guide for Natural Health Products (GUI-0158 v4.0) and the practical implications for companies operating in the Canadian market. The session focused on how the revised guidance reshapes expectations for quality systems, importer accountability, and end-to-end supply chain oversight, following its coming into force in March 2026.
This update represents the first full revision of the GMP guidance in over a decade and introduces a more structured, risk-based, and accountability-driven regulatory framework.
A Shift from Procedural Compliance to System Accountability
A key theme discussed during the webinar was Health Canada’s transition away from checklist-based compliance toward evaluating the effectiveness of a company’s quality system.
Under Version 4.0, the focus extends beyond whether procedures exist and places greater emphasis on how organizations:
- Identify and assess risk
- Implement and monitor controls
- Ensure consistency across the product lifecycle
This approach aligns more closely with established pharmaceutical GMP principles and requires organizations to demonstrate that their systems are not only documented, but effective and continuously maintained.
Expanded Responsibilities for Importers
As highlighted in the webinar, importers are subject to significantly expanded expectations under the updated guidance.
Importers are now expected to:
- Maintain documented and current evidence demonstrating GMP compliance at all foreign sites
- Establish and maintain robust supplier qualification programs, including quality agreements and audit mechanisms
- Conduct ongoing oversight of foreign manufacturers, packagers, and labelers
In practice, this means importers are expected to exercise a level of oversight over foreign partners that reflects their role as the Canadian site licence holder. Where deficiencies arise at the foreign site level, Health Canada may assess compliance at the level of the importer.
Quality Management System (QMS) as an Enterprise Function
The update emphasized that a fully implemented Quality Management System (QMS) is now a foundational requirement for all site licence holders.
Organizations must demonstrate:
- Clearly defined roles and responsibilities
- Controlled procedures across all GMP activities
- Active senior management involvement in quality oversight and decision-making
- Ongoing monitoring and continuous improvement of system performance
Quality is no longer limited to the quality unit. It must be integrated across all operational areas, including supplier management, storage, packaging, labelling, and distribution.
Formalization of Supply Chain Oversight
Another key shift is the increased clarity around GMP expectations for storage, distribution, transportation, and other outsourced activities.
Under Version 4.0, organizations are expected to:
- Establish formal quality agreements with contracted partners
- Conduct audits and ongoing monitoring of outsourced activities
- Verify that storage and handling conditions, including environmental controls, are appropriate and maintained
The updated guidance makes it clear that outsourced activities remain under the responsibility of the site licence holder, including where third-party service providers are used.
Strengthened Expectations for Evidence and Scientific Justification
The update also outlined increased expectations across several technical areas:
Foreign GMP Equivalence:
Importers must maintain comprehensive and current evidence packages for all foreign sites, including audit and monitoring records
Validation:
Manufacturing and analytical processes must be validated to demonstrate consistency, repeatability, and control
Stability Programs:
Real-time stability data is required to support shelf life under labelled storage conditions
Retention Samples:
Fully packaged samples must be retained, traceable, and available for testing
These expectations reinforce the need for well-documented, scientifically supported quality systems.
Documentation and Data Integrity
Documentation and data integrity were identified as critical focus areas under Version 4.0.
Organizations must ensure that records are:
- Attributable, legible, contemporaneous, original, and accurate
- Secure, traceable, and readily retrievable
- Supported by validated electronic systems with appropriate controls, including audit trails and user access restrictions
Documentation originating from foreign partners must be available in English or French. Where translation is required, it must be completed by a qualified translator or supported by an affidavit, with original records retained.
CAPA and Continuous Improvement
The webinar further addressed strengthened expectations for corrective and preventive action (CAPA) systems.
Organizations are expected to:
- Maintain formal deviation and investigation procedures
- Conduct structured root cause analyses
- Implement and verify corrective and preventive actions
- Monitor and trend quality data to identify recurring issues
Senior management involvement in CAPA oversight is now clearly expected, reinforcing accountability at the executive level.
Readiness and Next Steps
As highlighted during the webinar, organizations should prioritize the following actions to support compliance:
- Conduct a comprehensive gap assessment against Version 4.0 requirements
- Update SOPs, quality agreements, and supplier qualification programs
- Confirm that systems supporting documentation and data integrity are validated and controlled
- Train personnel across all operational levels
- Perform internal audits and mock inspections to assess inspection readiness
Ongoing alignment with the updated requirements is essential to mitigate compliance risk and maintain uninterrupted access to the Canadian market.
Final Remarks
Overall, Health Canada’s GMP Guide for Natural Health Products (GUI-0158 v4.0) reflects a more structured and accountability-driven approach to quality oversight across the full product lifecycle. The updated expectations require organizations to move beyond procedural compliance and demonstrate that their systems are actively managed, risk-informed, and supported by robust evidence. For importers and site licence holders, this includes maintaining clear oversight of foreign and outsourced activities, strengthening documentation and data integrity practices, and ensuring quality governance is visible at the executive level. As regulatory expectations continue to evolve, organizations that take a proactive and systems-based approach to compliance will be better positioned to maintain market access and support consistent product quality in Canada.
How SNI Supports GMP v4.0 Compliance
SNI supports organizations with tailored, end-to-end regulatory and quality solutions aligned with the updated GMP framework. Backed by over 20 years of industry experience and a longstanding role in supporting and contributing to the evolution of the NHP regulatory landscape in Canada, SNI brings both regulatory depth and practical insight to each engagement.
Our team is composed of experts from diverse backgrounds across the sector, enabling us to understand not only regulatory requirements, but also the commercial realities that shape business decisions. This integrated perspective allows us to deliver solutions that are both compliant and operationally viable, including QMS development and modernization, SOP creation, supplier qualification and foreign site evidence packages, gap assessments with targeted remediation strategies, stability and retention program review, and pre-inspection readiness support.
⬇️ Send us a request to learn more about labelling solutions
